Subsequently, to improve specificity, peritumoral epidermal AMBRA1 expression was assessed in combination with epidermal loricrin (as a marker of keratinocyte terminal differentiation), with the primary aim of this study to validate combined peritumoral AMBRA1 and loricrin (AMLo) expression as a prognostic biomarker for early‐stage melanoma. This evidence concerns the gene AMBRA1 and melanoma.